ArticleCase reports in cardiology2026
Mavacamten as an Effective Treatment for HCM With Latent Exercise-Induced Obstruction: A Case Report.
Article in Case reports in cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mavacamten as an Effective Treatment for HCM With Latent Exercise-Induced Obstruction: A Case Report.Case reports in cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by hypertrophy of the left ventricle that can lead to significant symptoms, particularly with exercise. For patients with HCM who demonstrate obstructive physiology, the first-in-class targeted cardiac specific myosin inhibitor, mavacamten, has been found to reduce the degree of obstruction as well as symptoms. Case Summary: We present a patient with symptomatic HCM who had no left ventricular outflow tract obstruction (LVOTO) at rest but demonstrated obstruction on treadmill stress echocardiography. She had symptomatic improvement after treatment with mavacamten. Discussion: Patients with symptomatic HCM who do not demonstrate elevated resting gradients may benefit from evaluation of exercise-induced gradients to diagnose obstructive HCM and guide initiation of targeted therapy with mavacamten. Take Home Message: Mavacamten may be safe and effective in patients who demonstrate LVOTO only upon provocation with exercise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.